ABRAXIS BIOSCIENCE RECEIVES MILESTONE PAYMENT FROM TAIHO PHARMACEUTICAL CO.

Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, today announced that it has received a $3 million milestone payment from Taiho Pharmaceutical Co., Ltd., (Taiho), for initiation of a Phase 1 clinical trial for ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060713005121&newsLang=en)